Maas BiolAB Demonstrates Mitochondrial Neuroprotection With Novel Cyclosporins at the 32nd Annual Meeting of the Society for Neuroscience.Business Editors/Biotechnology Writers BIOWIRE2K ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Nov. 12, 2002 Maas BiolAB scientists Eskil Elmer M.D., Ph.D. and Magnus Hansson M.D. presented two posters at the annual Society for Neuroscience For other uses, see SFN (disambiguation). The Society for Neuroscience (SfN) is a professional society for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. meeting in Orlando Florida. The titles of their presentations were: "CHARACTERIZATION OF CYCLOSPORIN INHIBITION OF CALCIUM-INDUCED PERMEABILITY TRANSITION IN RESPIRING CNS See Continuous net settlement. CNS See continuous net settlement (CNS). MITOCHONDRIA" and "POWERFUL CYCLOSPORIN INHIBITION OF CALCIUM-INDUCED PERMEABILITY TRANSITION IN BRAIN MITOCHONDRIA." These studies demonstrated the basis by which cyclosporin is neuroprotective, through its effect on preserving the mitochondrial mitochondrial pertaining to mitochondria. mitochondrial RNAs a unique set of tRNAs, mRNAs, rRNAs, transcribed from mitochondrial DNA by a mitochondrial-specific RNA polymerase, that account for about 4% of the total cell RNA that energy production, by specifically blocking the formation of lethal membrane megapores (permeability transition). By blocking mitochondrial megapores, cyclosporin prevents the toxic release of cytochrome c and other apoptosis-inducing factors which forces the nerve cell down a cell death pathway. The mitochondria are believed to be a final common pathway leading to neuronal death in many neurological diseases including traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain , stroke, Alzheimer's, Parkinson's, Huntington's and amyotrophic lateral sclerosis amyotrophic lateral sclerosis (ALS) (ā'mīətrōf`ik, sklĭrō`sĭs) or motor neuron disease, . Marcus Keep, M.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Maas reported "Our mitochondrial high-throughput screening techniques are evaluating new cyclosporin analogs with increased brain penetration and neuroprotection, and free from immunosuppression, which we are developing with academic, biotechnology and pharma partners. We will introduce a proprietary intravenous cyclosporin product NeuroSTAT(TM) for traumatic brain injury in the short-term, followed by patented second generation cyclosporin analogs with enhanced mitochondrial action for specific neurodegenerative diseases." Drs. Elmer and Hansson's mitochondrial laboratory is operating within the Experimental Brain Research Laboratory at the Wallenberg Neuroscience Center, Lund University in Lund, Sweden. Maas BiolAB is a privately held Swedish-American neuropharmaceutical corporation with world patents for cyclosporin neuroprotection. NeuroPharma AB in Lund, Sweden is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. . Maas BiolAB, LLC 1934 Quail Run Loop NE Albuquerque, NM 87122 USA +1-505-797-1020 tel +1-505-797-1024 fax NeuroPharma AB Magle Stora Kyrkogata 6 SE-223 50 Lund, Sweden +46-46-157763 tel +46-46-157716 fax http://www.maasbiolab.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion